glp-1 weight loss clinical trials GLP-1R Agonists for Oral GLP-1 Pill Delivers Injection-Like

The results of the TRANSCEND-T2D-1 trial, published in March 2026, showed that participants with type 2 diabetes mellitus, who took retatrutide 12mg, lost an average of 16.8% of their body weight at 40 weeks

Clinical studies show patients typically lose 7.7% of their body weight on semaglutide and up to 12.4% on tirzepatide after one year of treatment

Drucker and Habener showed that small quantities of laboratory-synthesized GLP-1 could trigger insulin

Research on obese mice suggests that unimolecular poly-pharmacology is an effective means to deal with various mechanisms leading to obesity and further indicates that GCGR activation is the distinguishing factor between single or double agonists and triple agonists of incretin receptors (127)

What they do is bring an out-of-control appetite back into a more normal range so people can make healthier choices